CLCKb mutation as a diagnostic therapeutical target

US7074573B2 · kind B2 · utility

Assignee

• Eberhard-Karls-Universität Tübingen Universitätsklinikum · DE

Inventors

• Florian Lang · Gilching, DE
• Siegfried Waldegger · Marburg, DE
• Phillipp Lang · Lörrach, DE
• Angelika Lampert · Lörrach, DE
• Hannsjoerg Seybert · Marburg, DE
• Nikola Jeck · Marburg, DE

Key dates

• Filing date: Oct 15, 2003
• Grant date: Jul 11, 2006
• Expiry date: Oct 15, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

The present invention relates to a method for diagnosing hypertension, and/or allergy, and/or hair loss, and/or liability for infection, of a human being, or a predisposition therefor; to a nucleic acid molecule coding for a human ClCKb protein comprising a genetic alteration at amino acid position 481 compared to the wild type, as well as for corresponding segments thereof; to a nucleic acid molecule which binds to the before-mentioned nucleic acid molecule under stringent conditions, as well as to a nucleic acid molecule which binds to that nucleic acid molecule; to a (poly)peptide encoded by the afore-mentioned nucleic acid molecules; to a method for identifying substances modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to a substance for modulating activity of a peptide derived from ClCKb protein that is genetically altered at amino acid position 481 compared to the wild type; to methods for preparing a pharmaceutical composition for treatment of hypertension, and/or allergy, and/or hair loss, and/or liability for infection; to pharmaceutical compositions; and to a method for treating …